zorifertinib
alpha biopharma,astrazeneca
['sclc', 'nsclc']
#asco23 zorifertinib superior to first-generation egfr tyrosine kinase inhibitors in egfr-mutant nsclc with central nervous system metastases - 
Associate Director Community Outreach- DEI- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed